Institutional Investors Increase AstraZeneca Holdings in Q3 2025

Several institutional investors increased their holdings in AstraZeneca PLC (NASDAQ:AZN) during the third quarter of 2025, according to recent SEC filings. Wealthcare Advisory Partners LLC boosted its stake by 558.1% after purchasing an additional 19,612 shares, bringing its holdings to 23,126 shares worth $1,774,000. Marks Group Wealth Management Inc increased its position by 20.6% after acquiring an additional 5,896 shares, with holdings valued at $2,643,000 as of its most recent SEC filing.

Bleakley Financial Group LLC increased its holdings by 8.4% during the third quarter after buying an additional 6,172 shares, bringing its total to 79,983 shares worth $6,136,000 at the end of the quarter. Synovus Financial Corp grew its holdings by 10.7% after acquiring an additional 7,583 shares, with its 78,315 shares valued at $6,009,000 as of its most recent SEC filing.

Among the largest institutional holders, Primecap Management Co. CA boosted its holdings by 1.3% in the second quarter after purchasing an additional 538,606 shares, bringing its total to 41,200,091 shares worth $2,879,062,000. Franklin Resources Inc. lifted its position by 0.9% in the second quarter, now holding 21,298,394 shares worth $1,488,332,000 after buying an additional 196,401 shares. Fisher Asset Management LLC boosted its stake by 2.6% in the second quarter, holding 20,695,979 shares worth $1,446,235,000 after buying an additional 530,520 shares. Jennison Associates LLC boosted its stake by 15.2% in the second quarter, now holding 12,167,365 shares worth $850,255,000 after buying an additional 1,605,133 shares. Ameriprise Financial Inc. grew its position by 2.1% during the second quarter, holding 5,046,992 shares valued at $351,734,000 after acquiring an additional 104,625 shares. Hedge funds and other institutional investors own 20.35% of the company's stock.

Shares of AstraZeneca opened at $206.43 on Friday. The company has a fifty day moving average of $124.40 and a two-hundred day moving average of $97.76. AstraZeneca PLC has a 52-week low of $122.48 and a 52-week high of $212.71. The firm has a market cap of $320.16 billion, a PE ratio of 68.58, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

The company recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 153.0%. AstraZeneca's dividend payout ratio is currently 74.83%.

Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. The company presently has an average rating of "Moderate Buy" and an average price target of $95.75. Wall Street Zen lowered shares of AstraZeneca from a "strong-buy" rating to a "buy" rating in a report on Saturday, January 17th. Deutsche Bank Aktiengesellschaft reissued a "sell" rating on shares of AstraZeneca in a report on Friday, February 6th. Guggenheim reaffirmed a "buy" rating on shares of AstraZeneca in a report on Wednesday, December 3rd.

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca's operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide. The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.